Featured News
View ASX Announcements here.
Starpharma presents promising additional clinical data for DEP® cabazitaxel in prostate cancer
Sep 12th, 2022
Starpharma announces additional results from the mCRPC cohort of its Phase 2 DEP® cabazitaxel trial, following completion of dosing in this cohort. Treatment with DEP® cabazitaxel showed a number of key advantages compared to published data for conventional cabazitaxel, including superior efficacy, as measured by longer PFS, and a lower incidence of key side effects, despite this patient cohort being relatively more heavily pre-treated.
Read More
Starpharma signs new DEP® agreement with MSD
Aug 10th, 2022
Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.
Read More
Starpharma to present DEP® at Boston ADC summit (ASX Announcement)
Apr 27th, 2022
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will today present as an invited speaker at the Novel Format Conjugates Summit, an industry conference focusing on next generation Non-Traditional Antibody Drug Conjugates (ADCs) for oncology and beyond.
Read More
Dr Jeff Davies appointed as non-executive director (ASX Announcement)
Apr 1st, 2022
Melbourne, Australia; 1 April 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that Dr Jeff Davies has commenced as an independent non-executive director, effective 1 April 2022. ... Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at... Read More
